CG Oncology, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

CG Oncology, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$4.04M	$1.14M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$190.77M	-$114.67M
Operating income as a percentage of revenue.	-4722.1%	-10067.3%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$161.00M	-$88.04M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.08	$-1.41
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.08	$-1.41

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$32.49M	$257.07M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$791.59M	$754.80M
All of the company's interest-bearing borrowings, short and long term combined.	$3.00M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$38.99M	$21.42M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$752.60M	$733.38M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$132.30M	-$78.70M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$134000	$234000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$132.43M	-$78.93M

Peer Comparison

	You	Peer avg
P/E	–	2.6
Revenue Growth	–	+43.4%
ROE	-26.4%	-241.9%